Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

NCT05345002 is registered in ClinicalTrials.gov with Stephen Bagley, MD, MSCE as lead sponsor.

NCT NCT05345002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05345002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
Lead sponsor
Stephen Bagley, MD, MSCE
Phase
Phase 2
Overall status
Recruiting
Start date
November 16, 2022
Completion date
June 1, 2028
Enrollment
55 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, glioma, idh mutation, oligodendroglioma